Alkermes' Alixorexton Shows Promising Phase 2 Results in Narcolepsy Type 1
Event summary
- Alkermes' Phase 2 Vibrance-1 study of alixorexton in adults with narcolepsy type 1 (NT1) published in The Lancet Neurology on August 24, 2026.
- Study showed statistically significant improvements in wakefulness and excessive daytime sleepiness across all dose groups (4 mg, 6 mg, 8 mg).
- Once-daily alixorexton demonstrated clinically meaningful improvements in cataplexy, fatigue, cognition, and quality of life.
- Alkermes has initiated the global Phase 3 Brilliance Studies for NT1 and NT2 based on positive Phase 2 results.
The big picture
Alkermes' positive Phase 2 data for alixorexton positions the company as a key player in the narcolepsy treatment landscape. The shift towards orexin 2 receptor agonists reflects broader industry trends in targeting wakefulness pathways for hypersomnolence disorders. The initiation of Phase 3 studies marks a critical step in validating alixorexton's potential to address unmet needs in NT1 and NT2, with broader implications for idiopathic hypersomnia (IH) and other neurological conditions.
What we're watching
- Clinical Progression
- Whether the Phase 3 Brilliance Studies will confirm the efficacy and safety of alixorexton in NT1 and NT2.
- Regulatory Pathway
- The pace at which the FDA and European Commission will review alixorexton given its Breakthrough Therapy and Orphan Drug Designations.
- Market Potential
- How alixorexton's potential to address multiple hypersomnolence disorders could expand its commercial opportunities.